Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Down 5.3% – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price fell 5.3% during mid-day trading on Thursday . The stock traded as low as $74.58 and last traded at $74.58. 250 shares changed hands during trading, a decline of 67% from the average session volume of 765 shares. The stock had previously closed at $78.73.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZLDPF shares. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday. Six equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Stock Up 3.5%

The stock has a market capitalization of $5.30 billion, a P/E ratio of 5.37 and a beta of 0.72. The stock has a 50 day moving average price of $76.50 and a 200-day moving average price of $68.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.21. The company had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. As a group, research analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.